Current Concepts

Drug Therapy for Parkinson's Disease

Authors: P. DAVID CHARLES MD, THOMAS L. DAVIS MD, Nashville, Tenn

Abstract

ABSTRACTParkinson's disease (PD) is a common neurodegenerative disease characterized by tremor, rigidity, bradykinesia, and loss of postural reflexes. Although the agents available for symptomatic treatment now allow most parkinsonian patients to live a normal life-span, these patients become progressively unable to participate in social functions, perform activities of daily living, and work. Therapy for PD may be associated with many complications that contribute to these disabilities. For this reason, education is helpful for the patient newly diagnosed with PD. Over the past 6 years, three new medications (selegiline, pergolide, and controlled-release levodopa) have been approved for use in Parkinson's disease. Other agents now available for the treatment of psychiatric illness may also be helpful in selected cases of PD. With this in mind, we review the commonly prescribed drugs and outline a rational plan for treatment of parkinsonism.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References